NSPR Stock Overview
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.98|
|52 Week High||US$6.82|
|52 Week Low||US$1.80|
|1 Month Change||-9.16%|
|3 Month Change||-39.44%|
|1 Year Change||-58.79%|
|3 Year Change||-96.17%|
|5 Year Change||-99.99%|
|Change since IPO||-100.00%|
Recent News & Updates
|NSPR||US Medical Equipment||US Market|
Return vs Industry: NSPR underperformed the US Medical Equipment industry which returned -24.7% over the past year.
Return vs Market: NSPR underperformed the US Market which returned -21.2% over the past year.
|NSPR Average Weekly Movement||6.5%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: NSPR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: NSPR's weekly volatility (7%) has been stable over the past year.
About the Company
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications.
InspireMD Fundamentals Summary
|NSPR fundamental statistics|
Is NSPR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NSPR income statement (TTM)|
|Cost of Revenue||US$3.90m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.94|
|Net Profit Margin||-345.80%|
How did NSPR perform over the long term?See historical performance and comparison
Is NSPR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NSPR?
Other financial metrics that can be useful for relative valuation.
|What is NSPR's n/a Ratio?|
Price to Sales Ratio vs Peers
How does NSPR's PS Ratio compare to its peers?
|NSPR PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
CEMI Chembio Diagnostics
RTSL Rapid Therapeutic Science Laboratories
RMTI Rockwell Medical
Price-To-Sales vs Peers: NSPR is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (8751.6x).
Price to Earnings Ratio vs Industry
How does NSPR's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: NSPR is good value based on its Price-To-Sales Ratio (3.5x) compared to the US Medical Equipment industry average (3.7x)
Price to Sales Ratio vs Fair Ratio
What is NSPR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3.5x|
|Fair PS Ratio||1.6x|
Price-To-Sales vs Fair Ratio: NSPR is expensive based on its Price-To-Sales Ratio (3.5x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).
Share Price vs Fair Value
What is the Fair Price of NSPR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NSPR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NSPR's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NSPR's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is InspireMD forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NSPR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NSPR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NSPR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NSPR's revenue (38.3% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: NSPR's revenue (38.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NSPR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has InspireMD performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NSPR is currently unprofitable.
Growing Profit Margin: NSPR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NSPR is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.
Accelerating Growth: Unable to compare NSPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NSPR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: NSPR has a negative Return on Equity (-54.39%), as it is currently unprofitable.
Discover strong past performing companies
How is InspireMD's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NSPR's short term assets ($32.6M) exceed its short term liabilities ($3.7M).
Long Term Liabilities: NSPR's short term assets ($32.6M) exceed its long term liabilities ($1.8M).
Debt to Equity History and Analysis
Debt Level: NSPR is debt free.
Reducing Debt: NSPR had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NSPR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NSPR has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 8.2% each year.
Discover healthy companies
What is InspireMD current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NSPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NSPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NSPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NSPR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NSPR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Marvin Slosman (57 yo)
Mr. Marvin L. Slosman has been President, Chief Executive Officer and Director of InspireMD, Inc. since January 1, 2020. Mr. Slosman served as Chief Operating Officer for MEDCURA Incorporated from May 2019...
CEO Compensation Analysis
Compensation vs Market: Marvin's total compensation ($USD1.64M) is above average for companies of similar size in the US market ($USD799.15K).
Compensation vs Earnings: Marvin's compensation has increased whilst the company is unprofitable.
Experienced Management: NSPR's management team is considered experienced (3 years average tenure).
Experienced Board: NSPR's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.
InspireMD, Inc.'s employee growth, exchange listings and data sources
- Name: InspireMD, Inc.
- Ticker: NSPR
- Exchange: NasdaqCM
- Founded: 2005
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$16.482m
- Shares outstanding: 8.32m
- Website: https://www.inspiremd.com
Number of Employees
- InspireMD, Inc.
- 4 Menorat Hamaor Street
- Tel Aviv
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/04 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.